{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:39Z","timestamp":1790894439531,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","arthroplastyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Arthroplasty"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.arth.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T00:46:07Z","timestamp":1497660367000},"page":"2628-2638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["2017 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty"],"prefix":"10.1016","volume":"32","author":[{"given":"Susan M.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Abdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Dasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Gewurz-Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sculco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Sporer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Stryker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Turgunbaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Brause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Gililland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Hurley-Rosenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Kirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Losina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolph","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arth.2017.05.001_bib1","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.arth.2017.05.001_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.berh.2012.07.014","article-title":"The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007","volume":"26","author":"Ravi","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3899\/jrheum.130617","article-title":"Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991\u20132005","volume":"41","author":"Mertelsmann-Voss","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.38384","article-title":"US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis","volume":"66","author":"Mertelsmann-Voss","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/art.38344","article-title":"Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts","volume":"66","author":"Nikiphorou","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/ard.2006.057067","article-title":"Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38231","article-title":"Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis","volume":"66","author":"Ravi","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/annrheumdis-2012-202758","article-title":"Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study","volume":"73","author":"Lin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.22497","article-title":"Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study","volume":"67","author":"Singh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.arth.2017.05.001_bib10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3899\/jrheum.151373","article-title":"Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty","volume":"43","author":"Roberts","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib11","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3899\/jrheum.140011","article-title":"Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis","volume":"41","author":"Goodman","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.150525","article-title":"Patients with rheumatoid arthritis have similar excellent outcomes after total knee replacement compared with patients with osteoarthritis","volume":"43","author":"Goodman","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3899\/jrheum.141251","article-title":"Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case\u2013control study","volume":"42","author":"LoVerde","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3899\/jrheum.121171","article-title":"Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement","volume":"40","author":"Johnson","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/666641","article-title":"The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification","volume":"33","author":"Berbari","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.arth.2017.05.001_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/art.24060","article-title":"Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis","volume":"59","author":"Bongartz","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib17","first-page":"573","article-title":"Management of perioperative tumour necrosis factor \u03b1 inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis","volume":"55","author":"Goodman","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arth.2017.05.001_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib19","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 27","key":"10.1016\/j.arth.2017.05.001_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.arth.2012.02.022","article-title":"Economic burden of periprosthetic joint infection in the United States","author":"Kurtz","year":"2012","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.arth.2017.05.001_bib21","first-page":"22","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices","volume":"60","year":"2011","journal-title":"MMWR"},{"key":"10.1016\/j.arth.2017.05.001_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arth.2017.05.001_bib23","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.arth.2017.05.001_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/ard.2003.015248","article-title":"How to monitor SLE in routine clinical practice","volume":"64","author":"Fernando","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.06.010","article-title":"Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus","volume":"Suppl 1","author":"Salmon","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.arth.2017.05.001_bib26","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jacc.2009.07.010","article-title":"2009 ACCF\/AHA focused update on perioperative \u03b2 blockade incorporated into the ACC\/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery","volume":"54","author":"American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.arth.2017.05.001_bib27","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1161\/CIRCULATIONAHA.109.192690","volume":"120","author":"Fleisher","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.arth.2017.05.001_bib28","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141 Suppl 2","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.arth.2017.05.001_bib29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2106\/JBJS.9408.EBO746","article-title":"American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"94","author":"Jacobs","year":"2012","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.arth.2017.05.001_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.arth.2017.05.001_bib31","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.arth.2017.05.001_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.arth.2017.05.001_bib33","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.arth.2017.05.001_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jclinepi.2015.11.017","article-title":"A\u00a0guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach","volume":"72","author":"Neumann","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.arth.2017.05.001_bib35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.arth.2017.05.001_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.arth.2017.05.001_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard.60.3.214","article-title":"Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery","volume":"60","author":"Grennan","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.RHU.0000062514.54375.bd","article-title":"Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis","volume":"9","author":"Tanaka","year":"2003","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib39","first-page":"CD000957","article-title":"Methotrexate for treating rheumatoid arthritis","volume":"6","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arth.2017.05.001_bib40","first-page":"S2664","article-title":"Flares occur frequently in RA patients undergoing arthroplasty [abstract]","volume":"67 Suppl","author":"Goodman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.arth.2017.05.001_bib42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arth.2017.05.001_bib43","first-page":"CD005468","article-title":"TNF-\u03b1 inhibitors for ankylosing spondylitis","volume":"4","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arth.2017.05.001_bib44","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3109\/14397595.2015.1014302","article-title":"Postoperative complications in patients with rheumatoid arthritis using a biological agent: a systematic review and meta-analysis","volume":"25","author":"Ito","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib45","first-page":"CD007356","article-title":"Rituximab for rheumatoid arthritis","volume":"1","author":"Lopez-Olivo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arth.2017.05.001_bib46","first-page":"CD007649","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","volume":"9","author":"Ruiz Garcia","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arth.2017.05.001_bib47","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3904\/kjim.2014.29.5.656","article-title":"Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials","volume":"29","author":"Song","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.arth.2017.05.001_bib48","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib49","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.arth.2017.05.001_bib50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40259-013-0074-x","article-title":"Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis","volume":"28","author":"Borba","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.arth.2017.05.001_bib51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","article-title":"Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"14","author":"He","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.arth.2017.05.001_bib52","first-page":"CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","volume":"5","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arth.2017.05.001_bib53","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis","volume":"33","author":"Machado","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.arth.2017.05.001_bib54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00590-012-1035-7","article-title":"Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population","volume":"23","author":"Li","year":"2013","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/annrheumdis-2012-202470","article-title":"Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement","volume":"72","author":"Schoels","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1631\/jzus.B1200057","article-title":"Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Lan","year":"2012","journal-title":"J\u00a0Zhejiang Univ Sci B"},{"key":"10.1016\/j.arth.2017.05.001_bib57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.arth.2017.05.001_bib58","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arth.2017.05.001_bib59","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","article-title":"The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Lee","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.arth.2017.05.001_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1756-185X.2009.01457.x","article-title":"Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis","volume":"13","author":"Katikireddi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.arth.2017.05.001_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2010.25.1.1","article-title":"Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis","volume":"25","author":"Storage","year":"2010","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.arth.2017.05.001_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00228-009-0754-0","article-title":"The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"An","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arth.2017.05.001_bib64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3083.2009.02296.x","article-title":"A\u00a0systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis","volume":"70","author":"Wiens","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.arth.2017.05.001_bib65","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib66","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib67","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2474-9-52","article-title":"Tumor necrosis factor \u03b1 drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety","volume":"9","author":"Alonso-Ruiz","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.arth.2017.05.001_bib68","first-page":"883","article-title":"Risks and benefits of tumor necrosis factor-\u03b1 inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials","volume":"35","author":"Saad","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib69","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib70","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.arth.2017.05.001_bib71","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/ard.2005.035287","article-title":"Long term safety of etanercept in elderly subjects with rheumatic diseases","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40264-015-0336-2","article-title":"Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"38","author":"Capogrosso Sansone","year":"2015","journal-title":"Drug Safety"},{"key":"10.1016\/j.arth.2017.05.001_bib73","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2015-eular.3288","article-title":"Risk of serious adverse effects associated with different biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [abstract]","volume":"74 (Suppl 2)","author":"Tarp","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib74","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/annrheumdis-2015-eular.2781","article-title":"Safety of anti-TNFs in RA patients in real life: results from a systematic literature review and meta-analyses from biologic registers [abstract]","volume":"74 (Suppl 2)","author":"De la Forest","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib75","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/annrheumdis-2014-eular.5331","article-title":"Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis patients: a systematic literature review and network meta-analysis [abstract]","volume":"73 (Suppl 2)","author":"Hochberg","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib76","first-page":"S997","article-title":"Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel[abstract]","volume":"65 (Suppl)","author":"Tarp","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib77","first-page":"852","article-title":"Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"36","author":"He","year":"2013","journal-title":"Drug Safety"},{"key":"10.1016\/j.arth.2017.05.001_bib78","doi-asserted-by":"crossref","first-page":"A74","DOI":"10.1136\/annrheumdis-2013-eular.276","article-title":"Risk of cancer, serious lung infections and death with biologics: a systematic review and network meta-analysis of randomized controlled trials (RCTs) [abstract]","volume":"72","author":"Singh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib79","first-page":"S93","article-title":"Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials","volume":"40","author":"Ahadieh","year":"2013","journal-title":"J\u00a0Pharmacokinetics Pharmacodynamics"},{"key":"10.1016\/j.arth.2017.05.001_bib80","first-page":"S1854","article-title":"The safety of anti-TNF biologic agents in rheumatoid arthritis: a meta-analysis of 35 RCTs [abstract]","volume":"64 Suppl","author":"Lin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib81","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1590\/S1984-82502012000400022","article-title":"Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis","volume":"48","author":"Venson","year":"2012","journal-title":"Brazil J Pharm Sci"},{"key":"10.1016\/j.arth.2017.05.001_bib82","first-page":"S878","article-title":"The risk of serious infection with and without anti-TNF therapy in rheumatoid arthritis and ankylosing spondylitis: a meta-analysis [abstract]","volume":"63 Suppl","author":"Cormier","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib83","doi-asserted-by":"crossref","first-page":"AB8","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.arth.2017.05.001_bib84","first-page":"1343","article-title":"Anti-TNF therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"37","author":"Rieder","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib85","first-page":"AB4","article-title":"Incidence of serious infectious events with methotrexate treatment: metaanalysis of randomized controlled trials","volume":"62","author":"Powers","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.arth.2017.05.001_bib86","first-page":"749","article-title":"Rituximab for rheumatoid arthritis: a meta-analysis and systematic review","volume":"2","author":"Volkmann","year":"2010","journal-title":"Clin Med"},{"key":"10.1016\/j.arth.2017.05.001_bib87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.curtheres.2007.12.001","article-title":"Abatacept for the treatment of rheumatoid arthritis: a review","volume":"68","author":"Kaine","year":"2007","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.arth.2017.05.001_bib88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","volume":"34 Suppl 1","author":"Nestorov","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10787-015-0229-0","article-title":"Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs","volume":"23","author":"Jinesh","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.arth.2017.05.001_bib90","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-\u03b1 monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.arth.2017.05.001_bib91","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.arth.2017.05.001_bib92","first-page":"417","article-title":"Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis","volume":"56","author":"Tarp","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arth.2017.05.001_bib93","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.arth.2017.05.001_bib94","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","article-title":"Off-label use of rituximab in systemic lupus erythematosus: a systematic review","volume":"29","author":"Murray","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib95","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib96","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.arth.2017.05.001_bib97","first-page":"1697","article-title":"Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]","volume":"Suppl 63","author":"Ahadieh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arth.2017.05.001_bib98","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arth.2017.05.001_bib99","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00264-016-3265-5","article-title":"Post-operative medical and surgical complications after primary total joint arthroplasty in solid organ transplant recipients: a case series","volume":"41","author":"Palmisano","year":"2017","journal-title":"Int Orthop"},{"key":"10.1016\/j.arth.2017.05.001_bib100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.arth.2015.10.007","article-title":"How do previous solid organ transplant recipients fare after primary total knee arthroplasty?","volume":"31","author":"Klement","year":"2016","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.arth.2017.05.001_bib101","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archsurg.143.12.1222","article-title":"Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature","volume":"143","author":"Marik","year":"2008","journal-title":"Arch Surg"},{"key":"10.1016\/j.arth.2017.05.001_bib102","first-page":"1","article-title":"Prevention of herpes zoster: recommendation of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.arth.2017.05.001_bib103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1874312920131210005","article-title":"Risk factors for infection following total joint arthroplasty in rheumatoid arthritis","volume":"7","author":"Somayaji","year":"2013","journal-title":"Open Rheumatol J"}],"container-title":["The Journal of Arthroplasty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883540317304011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883540317304011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:35:58Z","timestamp":1750358158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883540317304011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0883540317304011"],"URL":"https:\/\/doi.org\/10.1016\/j.arth.2017.05.001","relation":{},"ISSN":["0883-5403"],"issn-type":[{"value":"0883-5403","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2017 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty","name":"articletitle","label":"Article Title"},{"value":"The Journal of Arthroplasty","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arth.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc and the American College of Rheumatology. All rights reserved.","name":"copyright","label":"Copyright"}]}}